|
1
|
Calin GA, Sevignani C, Dumitru CD, Hyslop
T, Noch E, Yendamuri S, Shimizu M, Rattan S, Bullrich F, Negrini M
and Croce CM: Human microRNA genes are frequently located at
fragile sites and genomic regions involved in cancers. Proc Natl
Acad Sci USA. 101:2999–3004. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Yanaihara N, Caplen N, Bowman E, Seike M,
Kumamoto K, Yi M, Stephens RM, Okamoto A, Yokota J, Tanaka T, et
al: Unique microRNA molecular profiles in lung cancer diagnosis and
prognosis. Cancer Cell. 9:189–198. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Xi Y, Shalgi R, Fodstad O, Pilpel Y and Ju
J: Differentially regulated micro-RNAs and actively translated
messenger RNA transcripts by tumor suppressor p53 in colon cancer.
Clin Cancer Res. 12:2014–2024. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Wickramasinghe NS, Manavalan TT, Dougherty
SM, Riggs KA, Li Y and Klinge CM: Estradiol downregulates miR-21
expression and increases miR-21 target gene expression in MCF-7
breast cancer cells. Nucleic Acids Res. 37:2584–2595. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Volinia S, Calin GA, Liu CG, Ambs S,
Cimmino A, Petrocca F, Visone R, Iorio M, Roldo C, Ferracin M, et
al: A microRNA expression signature of human solid tumors defines
cancer gene targets. Proc Natl Acad Sci USA. 103:2257–2261. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Boren T, Xiong Y, Hakam A, Wenham R, Apte
S, Wei Z, Kamath S, Chen DT, Dressman H and Lancaster JM: MicroRNAs
and their target messenger RNAs associated with endometrial
carcinogenesis. Gynecol Oncol. 110:206–215. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Chung TK, Cheung TH, Huen NY, Wong KW, Lo
KW, Yim SF, Siu NS, Wong YM, Tsang PT, Pang MW, et al: Dysregulated
microRNAs and their predicted targets associated with endometrioid
endometrial adenocarcinoma in Hong Kong women. Int J Cancer.
124:1358–1365. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Gottardo F, Liu CG, Ferracin M, Calin GA,
Fassan M, Bassi P, Sevignani C, Byrne D, Negrini M, Pagano F, et
al: Micro-RNA profiling in kidney and bladder cancers. Urol Oncol.
25:387–392. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Yang GH, Wang F, Yu J, Wang XS, Yuan JY
and Zhang JW: MicroRNAs are involved in erythroid differentiation
control. J Cell Biochem. 107:548–556. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Guo Y, Chen Z, Zhang L, Zhou F, Shi S,
Feng X, Li B, Meng X, Ma X, Luo M, et al: Distinctive microRNA
profiles relating to patient survival in esophageal squamous cell
carcinoma. Cancer Res. 68:26–33. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Moncini S, Salvi A, Zuccotti P, Viero G,
Quattrone A, Barlati S, De Petro G, Venturin M and Riva P: The role
of miR-103 and miR-107 in regulation of CDK5R1 expression and in
cellular migration. PLoS One. 6:e200382011. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Feng H, Cheung AN and Xue WC:
Down-regulation and promoter methylation of tissue inhibitor of
metalloproteinase 3 in choriocarcinoma. Gynecol Oncol. 94:375–382.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Yegnasubramanian S, Kowalski J, Gonzalgo
ML, Zahurak M, Piantadosi S, Walsh PC, Bova GS, De Marzo AM, Isaacs
WB and Nelson WG: Hypermethylation of CpG islands in primary and
metastatic human prostate cancer. Cancer Res. 64:1975–1986. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Darnton SJ, Hardie LJ and Muc RS: Tissue
inhibitor of metalloproteinase-3 (TIMP-3) gene is methylated in the
development of esophageal adenocarcinoma: loss of expression
correlates with poor prognosis. Int J Cancer. 115:351–358. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Bachman KE, Herman JG, Corn PG, Merlo A,
Costello JF, Cavenee WK, Baylin SB and Graff JR:
Methylation-associated silencing of the tissue inhibitor of
metalloproteinase-3 gene suggest a suppressor role in kidney,
brain, and other human cancers. Cancer Res. 59:798–802.
1999.PubMed/NCBI
|
|
16
|
Kumar MS, Lu J, Mercer KL, Golub TR and
Jacks T: Impaired microRNA processing enhances cellular
transformation and tumorigenesis. Nat Genet. 39:673–677. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Baker AH, George SJ, Zaltsman AB, Murphy G
and Newby AC: Inhibition of invasion and induction of apoptotic
cell death of cancer cell lines by overexpression of TIMP-3. Br J
Cancer. 79:1347–1355. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Lou Y, Yang X, Wang F, Cui Z and Huang Y:
MicroRNA-21 promotes the cell proliferation, invasion and migration
abilities in ovarian epithelial carcinomas through inhibiting the
expression of PTEN protein. Int J Mol Med. 26:819–27.
2010.PubMed/NCBI
|
|
19
|
Song B, Wang C, Liu J, Wang X, Lv L, Wei
L, Xie L, Zheng Y and Song X: MicroRNA-21 regulates breast cancer
invasion partly by targeting tissue inhibitor of metalloproteinase
3 expression. J Exp Clin Cancer Res. 29:292010. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Bian J, Wang Y, Smith MR, Kim H, Jacobs C,
Jackman J, Kung HF, Colburn NH and Sun Y: Suppression of in vivo
tumor growth and induction of suspension cell death by tissue
inhibitor of metalloproteinases (TIMP)-3. Carcinogenesis.
17:1805–1811. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Finan KM, Hodge G, Reynolds AM, Hodge S,
Holmes MD, Baker AH and Reynolds PN: In vitro susceptibility to the
proapoptotic effects of TIMP-3 gene delivery translates to greater
in vivo efficacy versus gene delivery for TIMPs-1 or -2. Lung
Cancer. 53:273–284. 2006. View Article : Google Scholar : PubMed/NCBI
|
